Avance Clinical solidifies its position as the leading early‑phase CRO in Australia—backed by rapid trial starts and generous …
Avance Clinical solidifies its position as the leading early‑phase CRO in Australia—backed by rapid trial starts and generous …
ViGeneron’s VG901 gains momentum with FDA rare pediatric disease status for CNGA1‑linked retinitis pigmentosa, while the EMA urges …
Multiple clinical-stage biotechs unveil bold 2025 roadmaps—from Denali’s upcoming BLA for Hunter syndrome to Cabaletta’s expanding autoimmune cell …
Mereo BioPharma’s Phase 3 study in osteogenesis imperfecta progresses to interim analysis, while alvelestat gains momentum toward EU orphan …
Bio‑Path outlines a robust development and regulatory path ahead, aiming to advance both cancer and obesity-focused therapies using …
The 43rd annual J.P. Morgan Healthcare Conference begins in San Francisco under tighter security and market uncertainty, but …
Hoyos’s inhaled mRNA-based therapy enters first-in-human testing for asthma—a milestone that could redefine treatment for chronic respiratory disease.
Stablepharma moves toward first-in-human testing of SPVX02, a thermally stable tetanus–diphtheria booster that could revolutionise vaccine storage and …
A three-year collaboration between Vertex and Orna Therapeutics brings cutting-edge lipid nanoparticle delivery into the spotlight, aiming to …
With a PDUFA date set for June 2025, the copper histidinate therapy may soon become the first FDA-approved …